(Calgary, Alberta, October 16, 2013) – Zephyr Sleep Technologies Inc. (Zephyr) is pleased to announce the following publications in the October issue of SLEEP:
- Research findings of Zephyr’s Chief Medical Officer, Dr. John Remmers outlining how “Remotely Controlled Mandibular Protrusion during Sleep Predicts Therapeutic Success with Oral Appliances in Patients with Obstructive Sleep Apnea”; and,
- Dr. Patrick Strollo provides an editorial “Another Advance in Oral Appliance Therapy?” on the research of Dr. Remmers et al.
Oral appliance therapy (OAT) has emerged as an effective alternative to the more common treatment, continuous positive airway pressure (CPAP) to treat obstructive sleep apnea (OSA). Until recently, there has been no standard or effective method to determine, in advance and at relatively low cost, the suitability of oral appliance therapy for OSA treatment. Dr. John Remmers’ study provides evidence which now allows sleep practitioners to accurately select patients and establish their target protrusive position required for efficacious therapy in a single night test. Dr. Patrick Strollo comments, “Remmers and colleagues provide evidence that a single night titration using a remote controlled mandibular positioner (RCMP) can predict success of oral appliance therapy”. The MATRx system is based on Zephyr’s proprietary RCMP technology.Dr. Remmers’ extensive research in the field of sleep medicine has led to a number of products and technologies. In 2010, Dr. Remmers and his team formed Zephyr Sleep Technologies to bring these products and technologies to market. The MATRx system was released in 2012. A MATRx study is performed in a sleep laboratory by a technician during a polysomnographic study (PSG test). With MATRx, sleep physicians will, for the first time, be able to reliably predict the effectiveness of oral appliance therapy as a treatment for OSA patients. “Understanding a patient’s airway response to mandibular protrusion is a critical component of confidently prescribing and delivering efficacious oral appliance therapy. For our patients, MATRx means we now have a tool that allows us to confidently prescribe oral appliance therapy” stated Dr. Remmers. “We know not all patients will respond to OAT, but many are looking for viable alternatives to CPAP. A MATRx test will determine, in a single night, whether OAT is a suitable alternative to CPAP.”A MATRx test not only determines who will respond to OAT, but also provides an effective target protrusive position. Now, sleep dentists can focus on fit and patient needs with the knowledge of a therapeutic outcome. The MATRx single night study effectively replaces all other OAT diagnostics, which in some cases took months. “MATRx is a proprietary and revolutionary technology that increases the quality of care, lowers overall cost of treatment and reduces treatment time. Everyone wins – the sleep physician can confidently prescribe an alternative to CPAP, the sleep dentist can now provide therapy without guesswork and the patient is treated faster and more effectively” says Dr. Shouresh Charkhandeh, Zephyr’s Chief Dental Officer.
The MATRx test is available at over 50 sleep labs in the U.S. MATRx studies are reimbursed under existing codes used by sleep centers. “The MATRx system allows us to make better treatment decisions for our patients and provide a more comprehensive service to our community. The guesswork is reduced and the need to wake the patient during manual titration is gone.” states Dr. Haramandeep Singh, Medical Director of Tri-Valley Sleep Center in San Ramon, CA that uses the MATRx system.
MATRx, an FDA cleared product, is sold and available in the United States and will soon be available in Canada. Zephyr has authorized sales representatives and customer support teams located throughout Canada and the U.S. who can provide information about Zephyr products.
Zephyr Sleep Technologies is a privately held medical device company that develops, manufactures and sells innovative, scientifically-validated medical devices to improve sleep. Zephyr works with sleep labs, technicians, physicians, dentists and leading edge sleep researchers to improve the treatment for obstructive sleep apnea (OSA). MATRx was developed by Zephyr and is based on and powered by the proprietary and patented technology known as OATRx. Zephyr is based in Calgary, Alberta.
For more information, please visit www.zephyrsleep.com or contact: Mark Durston, Director of Sales and Distribution, Zephyr Sleep Technologies